View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 7, 2022

Antengene obtains approval for Phase I solid tumour trial in Australia

Antengene's ATG-037 is an oral, small-molecule inhibitor of the cluster of differentiation 73 (CD73).

Antengene has received the go ahead from the Bellberry Human Research Ethics Committee (HREC) in Australia to commence the Phase I STAMINA trial of the company’s ATG-037 to treat locally advanced or metastatic solid tumour patients. 

ATG-037 is an oral, small-molecule inhibitor of the cluster of differentiation 73 (CD73). CD73 produces adenosine, which causes immunosuppression in the microenvironment of the tumour.

The primary goal of this first-in-human trial is to analyse the safety, tolerability and initial efficacy of ATG-037 as a single agent or along with an immune checkpoint inhibitor (CPI) in individuals with locally advanced or metastatic solid tumours.

This will aid in determining a suitable dose of ATG-037 for Phase II trials.

Furthermore, the trial will analyse the pharmacology of the therapy as the secondary goal.

Antengene chief medical officer Kevin Lynch said: “Preclinical toxicology data suggests that ATG-037 will have a broad therapeutic window and further preclinical data suggests the potential for differentiated characteristics compared to other CD73 inhibitors.”

“ATG-037 also has the potential to be used in combination with several agents in the Antengene pipeline including ATG-101, a proprietary PD-L1/4-1BB bispecific antibody, demonstrating the in-house combinatory potential of our pipeline programmes.”

In preclinical studies, ATG-037 showed to defeat the ‘hook effect’ usually associated with anti-CD73 antibodies and demonstrated to have a wider therapeutic window in GLP toxicology studies.

The company dosed the first subject in the Phase I PROBE trial of ATG-101 in metastatic/advanced solid tumour and B-cell non-Hodgkin’s lymphoma (B-NHL) patients in Australia, in December last year.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU